KISSEI PHARMACEUTICAL CO.,LTD. [4547.T]
TOKYO, May 27 (Pulse News Wire) – Kissei Pharmaceutical CO.,LTD. (4547.T) announced today that it has submitted a manufacturing and marketing approval application for Altascidin (generic name) in Japan.
The drug targets relapsed or refractory acute myeloid leukemia patients with IDH1 gene mutations. Altascidin inhibits the metabolic enzyme isocitrate dehydrogenase 1 (IDH1), restoring normal cell differentiation and preventing tumor transformation. Kissei acquired exclusive development and sales rights for Japan, South Korea, and Taiwan from Rigel Pharmaceuticals, Inc. in September 2024. In the United States, Altascidin was approved in December 2022 for similar indications and is marketed by Rigel.
In Taiwan, Orient EuroPharma is developing the drug. Kissei focuses on researching and developing treatments for rare diseases and conditions lacking adequate therapies. The company aims to provide new treatment options for patients suffering from such illnesses. The impact of this filing on performance expectations is reflected in the consolidated earnings forecast published on May 11, 2026. For more detailed information, refer to the press releases dated September 4, 2024, and May 1, 2026.
🟢 Confidence: High AI-translated content.